PL362221A1 - Zastosowanie szczepu Lactobacillus zmniejszającego czynniki ryzyka związane z zespołem metabolicznym - Google Patents

Zastosowanie szczepu Lactobacillus zmniejszającego czynniki ryzyka związane z zespołem metabolicznym

Info

Publication number
PL362221A1
PL362221A1 PL01362221A PL36222101A PL362221A1 PL 362221 A1 PL362221 A1 PL 362221A1 PL 01362221 A PL01362221 A PL 01362221A PL 36222101 A PL36222101 A PL 36222101A PL 362221 A1 PL362221 A1 PL 362221A1
Authority
PL
Poland
Prior art keywords
strain
metabolic syndrome
risk factors
factors involved
reducing
Prior art date
Application number
PL01362221A
Other languages
English (en)
Other versions
PL203824B1 (pl
Inventor
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of PL362221A1 publication Critical patent/PL362221A1/pl
Publication of PL203824B1 publication Critical patent/PL203824B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
PL362221A 2000-11-10 2001-11-12 Zastosowanie szczepu Lactobacillus plantarum PL203824B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0004124A SE0004124D0 (sv) 2000-11-10 2000-11-10 New use
PCT/SE2001/002500 WO2002038165A1 (en) 2000-11-10 2001-11-12 Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome

Publications (2)

Publication Number Publication Date
PL362221A1 true PL362221A1 (pl) 2004-10-18
PL203824B1 PL203824B1 (pl) 2009-11-30

Family

ID=20281779

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362221A PL203824B1 (pl) 2000-11-10 2001-11-12 Zastosowanie szczepu Lactobacillus plantarum

Country Status (16)

Country Link
US (1) US20040048356A1 (pl)
EP (1) EP1331938B1 (pl)
JP (1) JP4200518B2 (pl)
KR (2) KR20080047628A (pl)
CN (1) CN1226039C (pl)
AT (1) ATE343392T1 (pl)
AU (2) AU2002214486B2 (pl)
CA (1) CA2434035C (pl)
DE (1) DE60124131T2 (pl)
DK (1) DK1331938T3 (pl)
ES (1) ES2269480T3 (pl)
NO (1) NO330992B1 (pl)
NZ (1) NZ525657A (pl)
PL (1) PL203824B1 (pl)
SE (1) SE0004124D0 (pl)
WO (1) WO2002038165A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117414A1 (en) * 1998-10-01 2001-07-25 Probi Ab Reduction of oxidative stress factors
CN1293185C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1313600C (zh) * 2002-10-30 2007-05-02 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293187C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
CN1293186C (zh) * 2002-10-30 2007-01-03 食品工业发展研究所 具有降低与同化胆固醇能力的新颖耐酸与耐胆盐乳杆菌分离株
SE527555C2 (sv) 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2007036230A1 (en) 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
RU2008134892A (ru) * 2006-01-27 2010-03-10 Даниско А/С (Dk) Применение пробиотичеких микроорганизмов для лечения и профилактики ожирения и связанных с ним расстройств
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
JP5201832B2 (ja) * 2006-12-25 2013-06-05 花王株式会社 脂肪分解促進用皮膚外用剤
JP2008214253A (ja) 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
EP2011506A1 (en) 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
KR101010914B1 (ko) * 2008-04-28 2011-01-26 주식회사 엔유씨전자 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄
EP2411027B1 (en) 2009-03-25 2014-11-19 Chr. Hansen A/S Use of a probiotic to regulate body weight
DK2808024T3 (da) 2009-06-19 2019-06-11 Dupont Nutrition Biosci Aps Bifidobakterier til behandling af kongestiv hjerteinsufficiens
MX348112B (es) 2009-12-22 2017-05-26 Probi Ab Composiciones no fermentadas que comprenden una fracción a base de cereal y un probiótico y usos de estos.
KR101426276B1 (ko) * 2012-08-16 2014-08-05 주식회사한국야쿠르트 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
KR101470995B1 (ko) * 2013-08-30 2014-12-09 주식회사 바이오리쏘스 프로피온산 생산능을 갖는 미생물 및 그를 포함하는 조사료 조성물
KR101500974B1 (ko) * 2014-08-22 2015-03-13 (주) 에이투젠 항염증 및 대사성질환 개선 효능을 가지는 락토바실러스 플란타룸 hac01 균주 및 이의 용도
CN105105145B (zh) * 2015-09-14 2022-04-22 吉林省命之元生物科技有限公司 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用
GB201519327D0 (en) 2015-11-02 2015-12-16 Optibiotix Health Ltd Composition
CN105567601A (zh) * 2016-01-29 2016-05-11 江苏绿科生物技术有限公司 一种植物乳杆菌及其应用
EP3580326A4 (en) 2017-02-10 2020-02-12 Perfect (China) Co. Ltd NEW PROBIOTIC BIFIDOBACTERIA STRAINS
US11571447B2 (en) 2017-05-26 2023-02-07 House Wellness Foods Corporation Composition for preventing, ameliorating or treating metabolic syndrome
KR102063772B1 (ko) * 2019-07-23 2020-01-08 주식회사 메디오젠 혈당 강하 효과 및 항산화 효과를 갖는 유산균
CN112126604B (zh) * 2020-09-30 2022-05-17 江南大学 一株可降低高血压发生风险因子的植物乳杆菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient

Also Published As

Publication number Publication date
CA2434035A1 (en) 2002-05-16
US20040048356A1 (en) 2004-03-11
DK1331938T3 (da) 2007-02-12
CN1486189A (zh) 2004-03-31
ES2269480T3 (es) 2007-04-01
JP2004520276A (ja) 2004-07-08
CA2434035C (en) 2011-06-07
DE60124131D1 (de) 2006-12-07
SE0004124D0 (sv) 2000-11-10
AU2002214486B2 (en) 2007-04-26
AU1448602A (en) 2002-05-21
EP1331938B1 (en) 2006-10-25
NO20032056L (no) 2003-05-08
PL203824B1 (pl) 2009-11-30
JP4200518B2 (ja) 2008-12-24
DE60124131T2 (de) 2007-03-29
NO330992B1 (no) 2011-09-05
EP1331938A1 (en) 2003-08-06
WO2002038165A1 (en) 2002-05-16
ATE343392T1 (de) 2006-11-15
KR20040018304A (ko) 2004-03-03
CN1226039C (zh) 2005-11-09
NO20032056D0 (no) 2003-05-08
KR20080047628A (ko) 2008-05-29
NZ525657A (en) 2005-05-27
KR100886728B1 (ko) 2009-03-04

Similar Documents

Publication Publication Date Title
AU1448602A (en) Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003040686A3 (en) Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
WO2001096377A3 (en) Vaccine for congenital tremors in pigs
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
EP1500403A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
EP1303501A4 (en) CYANOMETHYL-SUBSTITUTED THIAZOLIUM AND IMIDAZOLIUM COMPOUNDS AND TREATMENT OF DISEASES RELATED TO PROTEIN AGING
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
AU2003273967A1 (en) Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
AU4553700A (en) Substitution infusion fluid and citrate anticoagulation
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2001017517A3 (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer
WO2004083369A3 (fr) Composition de fixation tissulaire
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
AU2096897A (en) Serum cholesterol lowering agent
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1634605A3 (en) treatment of dyslipidemia in a patient having type 2 diabetes
CA2216887A1 (en) Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
EP1421945A4 (en) ABSORBENT / ADSORBENT OF BILARY ACID